FDA Approves Treatment for FXIII Deficiency

The U.S. Food and Drug Administration (FDA) has approved Corifact™, a plasma-derived factor XIII product, for the routine prophylactic treatment of congenital factor XIII (FXIII) deficiency. The FDA approval was made after positive results of a clinical study of 14 patients with congenital FXIII deficiency.

FXIII deficiency is a rare disease that affects 1 out of every 3 to 5 million people in the U.S., or approximately 150 people. The condition is characterized by blood that clots normally, but the clots are unstable, so bleeding recurs. READ MORE